

Samantha Culos^{1,2}, Sonya Cressman^{1,2}, Peter Malone³, David Whitehurst², Helen McTaggart-Cowan^{1,2}, Cynthia Toze^{1,4}, Alina Gerrie^{1,4}, Raewyn Broady^{1,4}, Stuart Peacock^{1,2}

¹ BC Cancer, ² Faculty of Health Sciences, Simon Fraser University, ³ Cell Therapy and Transplant Canada, ⁴ Leukemia/Bone Marrow Transplant Program of BC

Introduction

- Acute Myeloid Leukemia (AML) is a serious cancer affecting the blood and bone marrow
- Patients are required to stay in hospital for several weeks to receive intensive treatment
- AML treatment has shown to impact Quality of Life (QoL) (1); however further information is needed to develop questions which best capture QoL in this patient group (2)
- Investigating patient reported outcomes can help improve patient-centered care


Study purpose

- 1.) To gain insight on which aspects of QoL and wellbeing **matter most to patients** with AML
- 2.) To **partner with patients** to design collaborative care plans for community-based settings

Methods

Pilot Study Launch Date: May 2019

Location: Vancouver General Hospital



Questionnaires

- EQ-5D-5L, ICECAP-A, EORTC QLQ-C30, Demographics

Debriefing Interview


- Questionnaire feedback & research team participation

Preliminary Findings


“How well did these questionnaires reflect your experience with blood cancer?”

64% “Not at all” or “A little bit”
29% “Quite a bit”
7% “Very much”

“What has had the most impact on your QoL since treatment?”



“Would you be interested in further contributing to this study by participating as part of the research team?”



Implications

- Guide policy regarding which QoL questions are routinely used to assess AML patients
- Ability to partner with patients to design follow-up care plans

Knowledge Translation

We will continue to share this information with physicians through conferences

Acknowledgements

This study is being conducted by BC Cancer and the Leukemia/Bone Marrow Transplant Program of BC, and is sponsored by the VGH and UBC Hospital Foundation and the Canadian Centre for Applied Research in Cancer Control (ARCC). ARCC is funded by the Canadian Cancer Society Research Institute.

1. Leunis A, Redekop WK, Uyl-de Groot CA, Löwenberg B. Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. *European journal of haematology*. 2014 Sep;93(3):198-206.
2. Buckley SA, Kirtane K, Walter RB, Lee SJ, Lyman GH. Patient-reported outcomes in acute myeloid leukemia: where are we now?. *Blood reviews*. 2018 Jan 1;32(1):81-7.